Pfizer disclosed plans to launch 15 new studies in obesity next year, including multiple Phase III programs, as it seeks to shore up revenue facing a looming patent cliff. The initiative signals Pfizer’s strategic pivot into metabolic disease and weight‑loss therapeutics, an intensely competitive space led by GLP‑1 and combination regimens. The company’s programmatic expansion underscores how major pharma is reallocating R&D capacity to obesity to replace expiring sales.